Last reviewed · How we verify
111In-DAC
A radiolabeled antibody-drug conjugate targeting CD19
A radiolabeled antibody-drug conjugate targeting CD19 Used for B-cell malignancies.
At a glance
| Generic name | 111In-DAC |
|---|---|
| Sponsor | Copharos |
| Drug class | Monoclonal antibody-drug conjugate |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
111In-DAC is a monoclonal antibody-drug conjugate that targets CD19-positive B-cell malignancies. The drug consists of a monoclonal antibody linked to a cytotoxic agent via a linker molecule, which is conjugated to a radioactive isotope (111In). This allows for targeted delivery of radiation to cancer cells expressing CD19.
Approved indications
- B-cell malignancies
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer (PHASE1)
- Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 111In-DAC CI brief — competitive landscape report
- 111In-DAC updates RSS · CI watch RSS
- Copharos portfolio CI